Endo raises full-year guidance despite Q3 income drop
This article was originally published in Scrip
Executive Summary
Endo Pharmaceuticals reported a drop of 25% in income for the third quarter to $49 million, primarily owing to Indevus acquisition expenses. However, revenues increased by 14% to $361 million and the company is raising its guidance for full-year figures.